We are a commercial-stage diagnostics company that is fully committed to delivering solutions that reshape the way diagnostics is practiced.
Our fundamental objective is to empower our customers to realize their full potential and improve their business. Together, we are transforming transfusion diagnostics and beyond.
Originally established in Scotland in the 1940s as Alba Bioscience, Quotient’s then research and manufacturing subsidiary manufactured blood typing reagents as part of the Scottish National Blood Transfusion Service (SNBTS). In addition to supplying its products throughout the Scottish National Health System, Alba Bioscience expanded its operations and subsequently emerged as an original equipment manufacturer (OEM) supplier to the world’s leading transfusion diagnostics companies. In 2007, Alba Bioscience was privatized and became part of what is now known as Quotient.
Building on our strong heritage in transfusion diagnostics, in 2013, we introduced our proprietary multimodality multiplexing microarray technology, MosaiQ™, which represents the world’s first fully automated, consolidated testing platform. MosaiQ™ is a game-changing solution that was designed to increase efficiencies, improve clinical practice, deliver significant workflow improvements, and reduce operational costs within laboratories throughout the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient currently has offices in Eysins, Switzerland; Edinburgh, Scotland; and Newtown, Pennsylvania.